Market capitalization | $334.92m |
Enterprise Value | $160.40m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.84 |
P/S ratio (TTM) P/S ratio | 3.83 |
P/B ratio (TTM) P/B ratio | 1.57 |
Revenue growth (TTM) Revenue growth | -77.06% |
Revenue (TTM) Revenue | $87.37m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
4 Analysts have issued a Amylyx Pharmaceuticals forecast:
4 Analysts have issued a Amylyx Pharmaceuticals forecast:
Dec '24 |
+/-
%
|
||
Revenue | 87 87 |
77%
77%
|
|
Gross Profit | -38 -38 |
111%
111%
|
|
EBITDA | -255 -255 |
739%
739%
|
EBIT (Operating Income) EBIT | -256 -256 |
759%
759%
|
Net Profit | -302 -302 |
712%
712%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Josh Klee |
Employees | 123 |
Founded | 2013 |
Website | www.amylyx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.